Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer

Journal of Clinical Oncology

Volumn 32, Issue 32, 2014, Pages 3626-3634

  Saura, Cristina ^a   Garcia Saenz, Jose A ^b   Xu, Binghe ^d   Harb, Wael ^e   Moroose, Rebecca ^f   Pluard, Timothy ^g   Cortés, Javier ^a   Kiger, Corinne ^h   Germa, Caroline ⁱ   Wang, Kongming ^h   Martin, Miguel ^c   Baselga, José ^j   Kim, Sung Bae ^k  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d CANCER HOSPITAL   (China)

^e Horizon Medical Group   (United States)

^f UNIVERSITY OF FLORIDA HEALTH   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h PFIZER INC   (United States)

ⁱ NOVARTIS PHARMA K K   (Japan)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k University of Ulsan College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CAPECITABINE; NERATINIB; THROMBOPLASTIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FLUOROURACIL; LAPATINIB; MONOCLONAL ANTIBODY; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASCITES; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENERAL CONDITION DETERIORATION; HAND FOOT SYNDROME; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PARESTHESIA; PATHOLOGY; SYNDROME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CAPECITABINE; DEOXYCYTIDINE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PARESTHESIA; QUINAZOLINES; QUINOLINES; RECEPTOR, ERBB-2; SYNDROME; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84911943039     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.3809     Document Type: Article

References (28)

1. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
2. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
5. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
6. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005
7. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
8. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533-543, 2008
9. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
10. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
11. Nahta R, Esteva F: HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8:215, 2006
12. Rabindran SK, Discafani CM, Rosfjord EC, et al: Antitumor activity of HKI-272, an orally active, rreversible inhibitor of the HER-2 tyrosine kinase Cancer Res 64:3958-3965, 2004
13. Tsou HR, Overbeek-Klumpers EG, Hallett WA, et al: Optimization of 6, 7-disubstituted-4-(arylamino) quinoline-3-carbonitriles as orally active, rreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem 48 1107-1131, 2005
14. Burstein HJ, Sun Y, Dirix LY, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307, 2010
15. Wong KK, Fracasso PM, Bukowski RM, et al A phase I study with neratinib (HKI-272), an irreversble pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15:2552-2558, 2009
16. Martin M, Bonneterre J, Geyer CE Jr, et al: A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer 49:3763-3772, 2013
17. Sutherland S, Ashley S, Miles D, et al: Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases-the UK experience. Br J Cancer 102:995-1002, 2010
18. Capri G, Chang J, Chen SC, et al: An openlabel expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 21:474-480, 2010
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
20. Chang M: Adaptive Design Theory and Implementation Using SAS and R. Boca Raton, FL, Chapman Hall/CRC, 2008
21. Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al: Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14:1227-1233, 2003
22. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005
23. Fumoleau P, Largillier R, Clippe C, et al: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536-542, 2004
24. Chien AJ, Rugo HS: The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf 9:335-346, 2010
25. Swaby R, Blackwell K, Jiang Z, et al: Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study. J Clin Oncol 27:42s, 2009 (suppl; abstr 1004)
26. Chow LW, Xu B, Gupta S, et al: Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer 108:1985-1993, 2013
27. Gandhi L, Bahleda R, Tolaney SM, et al: Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 32:68-75, 2014
28. Awada A, Dirix L, Manso Sanchez L, et al: Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol 24:109-116, 2013